Back to Browse Journals » Biologics: Targets and Therapy » Volume 4

New and emerging treatment approaches to lupus

Authors Marion Haubitz

Published Date September 2010 Volume 2010:4 Pages 263—271

DOI http://dx.doi.org/10.2147/BTT.S7581

Published 6 September 2010

Marion Haubitz
Department of Nephrology, Medical School Hannover, Hanover, Germany
Abstract: The main goal in systemic lupus erythematosus (SLE) is to achieve remission, as this has a major impact on patient and renal survival. Furthermore, early treatment success has been shown to improve long-term prognosis. Treatment in severe SLE, especially in lupus nephritis, has traditionally been a standardized schematic therapy with cyclophosphamide and prednisolone followed by azathioprine. However, animal and human studies have increased our pathogenetic knowledge of this autoimmune disease with emerging new treatment targets. New and future therapeutic approaches are focused on B-cell depletion, T-cell downregulation and co-stimulatory blockade, cytokine inhibition, or the modulation of complement. Many different biological agents have been used in recent and ongoing studies, but up to now breakthroughs emerging from randomized Phase III trials have been rare. However, the future remains exciting with progress towards safe treatments with which to control the disease in the long run.
Keywords: systemic lupus erythematosus, lupus nephritis, B-cell depletion, co-stimulatory blockade, cytokine inhibition, monoclonal antibodies

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review

Colucci L, Bosco M, Ziello AR, Rea R, Amenta F, Fasanaro AM

Journal of Experimental Pharmacology 2012, 4:163-172

Published Date: 12 December 2012

Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus

Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C

Journal of Experimental Pharmacology 2012, 4:149-155

Published Date: 23 October 2012

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

Wiesik-Szewczyk E, Olesinska M

Biologics: Targets and Therapy 2012, 6:347-354

Published Date: 26 September 2012

The role of epigenetic mechanisms and processes in autoimmune disorders

Greer JM, McCombe PA

Biologics: Targets and Therapy 2012, 6:307-327

Published Date: 6 September 2012

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Health literacy and health seeking behavior among older men in a middle-income nation

Paul A Bourne, Chloe Morris, Christopher AD Charles, et al

Patient Related Outcome Measures 2010, 1:39-49

Published Date: 26 May 2010

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009